The French Supreme Court upholds dismissal of the Competition Authority’s decision sanctioning predatory pricing in the market for sodic cefuroxime (GlaxoSmithKline)

On 17 March 2009, the French Supreme Court confirmed a case dated 8 April 2008 in which the Paris Court of Appeal overruled a decision by the French NCA (the “NCA”) sanctioning GlaxoSmithLine (“GSK”) for predatory pricing in the market for sodic cefuroxime. Background This case does not reflect common predatory pricing cases. First, the alleged abusive practice occurred in a non-dominated market. According to the NCA, GSK had used predatory pricing in the market for sodic cefuroxime (Zinnat injectable) in which it did not hold any dominant position, in order to protect its dominant position in the market for injectable acyclovir (Zovirax). Second, the alleged abusive conduct relied on a predatory strategy based on reputation effect on the dominated market. According to the NCA, GSK's

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • Juliette Goyer Avocat (Paris)
  • Belgium Competition Authority (Brussels)

Citation

Juliette Goyer, Suzanne Jude, The French Supreme Court upholds dismissal of the Competition Authority’s decision sanctioning predatory pricing in the market for sodic cefuroxime (GlaxoSmithKline), 17 mars 2009, e-Competitions March 2009, Art. N° 26440

Visites 1956

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues